Latest News
Lakewood-Amedex expands intellectual property portfolio with Australian Bisphosphocin patent
22 June 2026 - Biotechnology company Lakewood-Amedex Biotherapeutics Inc (NASDAQ: LABT) announced on Monday that it has secured a new composition of matter patent from IP Australia covering its Bisphosphocin compounds, strengthening its global intell...
Genprex receives Canadian Patent Allowance for Reqorsa gene therapy combination in lung cancer
22 June 2026 - Gene therapy company Genprex Inc (NASDAQ: GNPX) disclosed on Monday that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering the use of its Reqorsa gene therapy (quaratusugene ozep...
Transgene expands myvac platform into non-small cell lung cancer with TG4070
22 June 2026 - French biotech company Transgene (Euronext Paris:TNG) announced on Monday that it has initiated a randomised Phase 1 trial of TG4070, an individualised neoantigen therapeutic vaccine, in combination with nivolumab for the adjuvant trea...
BioArctic and Eli Lilly enter BrainTransporter collaboration with up to USD800m in milestone payments
22 June 2026 - Swedish research-based biopharmaceutical company BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) reported on Monday that it has entered into a research and collaboration agreement with US pharmaceutical firm Eli Lilly and Company to dev...
Fusion Antibodies secures Canadian patent allowance for antibody library technology
22 June 2026 - Belfast-based contract research organisation Fusion Antibodies plc (AIM: FAB) declared on Monday that it has received a notice of allowance from the Canadian Intellectual Property Office for patent application no. 3,115,150 covering tw...